Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients
M. Best
(1)
,
M. Jachiet
(2)
,
Nicolas Molinari
(1, 3)
,
F. Manna
(1)
,
Christian Girard
(1)
,
V. Pallure
(4)
,
A. Cosnes
(5)
,
D. Lipsker
(6, 7)
,
T. Hubiche
(8)
,
J.-L. Schmutz
(9)
,
Y. Le Corre
(10)
,
N. Cordel
(11)
,
M. Dandurand
(12)
,
O. Dereure
(13, 1)
,
B. Guillot
(13, 1)
,
A. Du-Thanh
(13, 1)
,
C. Bulai Livideanu
(14)
,
F. Chasset
(15)
,
J.D. Bouaziz
(2)
,
C. Frances
(15)
,
D. Bengoufa
(16)
,
T. Vincent
(1, 17)
,
D. Bessis
(1, 13)
,
Emsed Étude Des Maladies Systémiques En Dermatologie
1
CHRU Montpellier -
Centre Hospitalier Régional Universitaire [Montpellier]
2 Service de dermatologie [Paris]
3 IMAG - Institut Montpelliérain Alexander Grothendieck
4 Centre Hospitalier Saint Jean de Perpignan
5 Service de dermatologie [Mondor]
6 UNISTRA - Université de Strasbourg
7 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
8 CHI Fréjus - St Raphaël - Centre Hospitalier Intercommunal Fréjus - St Raphaël
9 Service de Dermatologie et Allergologie [CHRU Nancy]
10 CHU Angers - Centre Hospitalier Universitaire d'Angers
11 CHU Pointe-à-Pitre/Abymes [Guadeloupe]
12 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
13 Pathogénèse et contrôle des infections chroniques (PCCI)
14 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
15 CHU Tenon [AP-HP]
16 Service d'Immunopathologie [Hôpital Saint-Louis, Paris]
17 UM - Université de Montpellier
2 Service de dermatologie [Paris]
3 IMAG - Institut Montpelliérain Alexander Grothendieck
4 Centre Hospitalier Saint Jean de Perpignan
5 Service de dermatologie [Mondor]
6 UNISTRA - Université de Strasbourg
7 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
8 CHI Fréjus - St Raphaël - Centre Hospitalier Intercommunal Fréjus - St Raphaël
9 Service de Dermatologie et Allergologie [CHRU Nancy]
10 CHU Angers - Centre Hospitalier Universitaire d'Angers
11 CHU Pointe-à-Pitre/Abymes [Guadeloupe]
12 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
13 Pathogénèse et contrôle des infections chroniques (PCCI)
14 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
15 CHU Tenon [AP-HP]
16 Service d'Immunopathologie [Hôpital Saint-Louis, Paris]
17 UM - Université de Montpellier
M. Jachiet
- Fonction : Auteur
- PersonId : 786587
- ORCID : 0000-0001-5286-9689
Nicolas Molinari
- Fonction : Auteur
- PersonId : 173223
- IdHAL : nicolas-molinari
- ORCID : 0000-0002-1786-0088
- IdRef : 112380425
Christian Girard
- Fonction : Auteur
- PersonId : 18241
- IdHAL : christian-girard
- IdRef : 069226091
D. Lipsker
- Fonction : Auteur
- PersonId : 765615
- ORCID : 0000-0003-4675-0336
- IdRef : 063760371
N. Cordel
- Fonction : Auteur
- PersonId : 1255118
- ORCID : 0000-0003-1679-8005
- IdRef : 108964000
O. Dereure
- Fonction : Auteur
- PersonId : 759260
- ORCID : 0000-0001-8736-1922
D. Bengoufa
- Fonction : Auteur
- PersonId : 786588
- ORCID : 0000-0003-1608-7510
Emsed Étude Des Maladies Systémiques En Dermatologie
- Fonction : Auteur
Résumé
BACKGROUND:Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype.OBJECTIVE:We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA.METHODS:A 3.5-year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis.RESULTS:MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation-associated protein-5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor-1 antibodies (11.1%), antinuclear matrix protein-2 antibodies (6.8%) and antiaminoacyl-transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1).CONCLUSION:Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.